$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000143853322000032 Filed on August 04, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$53.50M	$54.17M	$48.49M
YoY Change	-21.58%	-0.82%	2.28%
Cost Of Revenue	$1.675M	$2.051M	$2.138M
YoY Change	5.21%	24.23%	29.97%
Gross Profit	$51.82M	$52.12M	$46.35M
YoY Change	-22.22%	-1.6%	1.28%
Gross Profit Margin	96.87%	96.21%	95.59%
Selling, General & Admin	$57.52M	$52.98M	$46.79M
YoY Change	59.49%	51.52%	27.22%
% of Gross Profit	111.0%	101.66%	100.95%
Research & Development	$59.26M	$59.68M	$56.61M
YoY Change	22.41%	15.2%	18.07%
% of Gross Profit	114.35%	114.52%	122.14%
Depreciation & Amortization	$8.578M	$8.108M	$7.092M
YoY Change	8.95%	22.4%	16.76%
% of Gross Profit	16.55%	15.56%	15.3%
Operating Expenses	$116.8M	$112.7M	$103.4M
YoY Change	38.24%	29.83%	22.04%
Operating Profit	-$68.13M	-$65.45M	-$66.13M
YoY Change	114.86%	85.33%	39.08%
Interest Expense	-$2.892M	-$2.972M	-$2.515M
YoY Change	-40.97%	-38.75%	-52.73%
% of Operating Profit
Other Income/Expense, Net	-$1.377M	-$1.528M	-$9.789M
YoY Change	-64.56%	-58.11%	63.01%
Pretax Income	-$69.51M	-$66.98M	-$75.92M
YoY Change	95.28%	71.9%	41.76%
Income Tax	$145.0K	$53.00K	$100.0K
% Of Pretax Income
Net Earnings	-$69.66M	-$67.03M	-$75.97M
YoY Change	95.45%	71.82%	41.03%
Net Earnings / Revenue	-130.21%	-123.75%	-156.68%
Basic Earnings Per Share	-$1.09	-$1.05	-$1.20
Diluted Earnings Per Share	-$1.09	-$1.05	-$1.20
COMMON SHARES
Basic Shares Outstanding	63.96M shares	63.64M shares	63.13M shares
Diluted Shares Outstanding	64.03M shares	63.64M shares	63.13M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$448.1M	$508.8M	$529.7M
YoY Change	-1.04%	23.63%	22.89%
Cash & Equivalents	$151.3M	$179.8M	$256.6M
Short-Term Investments	$296.8M	$329.0M	$273.1M
Other Short-Term Assets	$8.549M	$9.283M	$6.507M
YoY Change	13.93%	26.49%	-2.88%
Inventory	$7.297M	$7.632M	$6.521M
Prepaid Expenses
Receivables	$12.70M	$16.70M	$14.70M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$534.8M	$586.8M	$631.1M
YoY Change	-7.64%	6.73%	11.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.557M	$10.08M	$10.60M
YoY Change	-16.99%	-13.99%	-9.36%
Goodwill	$900.0K	$900.0K	$900.0K
YoY Change	-3.85%	-3.85%	-3.85%
Intangibles	$149.5M	$149.9M	$153.3M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$11.09M	$10.81M	$10.83M
YoY Change	-68.19%	-68.55%	-69.08%
Total Long-Term Assets	$191.4M	$192.7M	$197.3M
YoY Change	-2.36%	-2.16%	-0.85%
TOTAL ASSETS
Total Short-Term Assets	$534.8M	$586.8M	$631.1M
Total Long-Term Assets	$191.4M	$192.7M	$197.3M
Total Assets	$726.2M	$779.5M	$828.4M
YoY Change	-6.3%	4.38%	8.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.01M	$11.85M	$18.43M
YoY Change	140.31%	42.01%	22.83%
Accrued Expenses	$88.38M	$82.69M	$69.24M
YoY Change	39.61%	32.38%	49.01%
Deferred Revenue	$11.38M	$12.50M	$14.23M
YoY Change	-29.16%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$131.0M	$124.5M	$119.5M
YoY Change	15.79%	28.37%	40.53%
LONG-TERM LIABILITIES
Long-Term Debt	$375.1M	$374.7M	$374.3M
YoY Change	67.69%	69.65%	71.63%
Other Long-Term Liabilities	$9.304M	$9.605M	$10.35M
YoY Change	-78.49%	-78.03%	-76.02%
Total Long-Term Liabilities	$9.304M	$9.605M	$10.35M
YoY Change	-78.49%	-78.03%	-76.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$131.0M	$124.5M	$119.5M
Total Long-Term Liabilities	$9.304M	$9.605M	$10.35M
Total Liabilities	$625.5M	$622.8M	$620.3M
YoY Change	33.75%	50.26%	54.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$948.4M	-$878.7M	-$811.7M
YoY Change	32.76%	29.46%	26.88%
Common Stock	$6.000K	$6.000K	$6.000K
YoY Change	-100.0%	-100.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$100.7M	$156.7M	$208.1M
YoY Change
Total Liabilities & Shareholders Equity	$726.2M	$779.5M	$828.4M
YoY Change	-6.3%	4.38%	8.42%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$69.66M	-$67.03M	-$75.97M
YoY Change	95.45%	71.82%	41.03%
Depreciation, Depletion And Amortization	$8.578M	$8.108M	$7.092M
YoY Change	8.95%	22.4%	16.76%
Cash From Operating Activities	-$39.53M	-$36.81M	-$55.32M
YoY Change	-223.27%	-666.94%	108.96%
INVESTING ACTIVITIES
Capital Expenditures	-$7.633M	-$11.46M	$131.0K
YoY Change	42.04%	166.08%	-97.09%
Acquisitions
YoY Change
Other Investing Activities	$17.71M	-$27.64M	$38.43M
YoY Change	-53.26%	-59.06%	-139.85%
Cash From Investing Activities	$10.08M	-$39.10M	$33.17M
YoY Change	-69.01%	-45.55%	-131.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.278M	831.0K	$113.9M
YoY Change	-5.63%	171.57%	-41.81%
NET CHANGE
Cash From Operating Activities	-39.53M	-36.81M	-$55.32M
Cash From Investing Activities	10.08M	-39.10M	$33.17M
Cash From Financing Activities	2.278M	831.0K	$113.9M
Net Change In Cash	-27.17M	-75.07M	$90.82M
YoY Change	-140.55%	15.48%	43.11%
FREE CASH FLOW
Cash From Operating Activities	-$39.53M	-$36.81M	-$55.32M
Capital Expenditures	-$7.633M	-$11.46M	$131.0K
Free Cash Flow	-$31.89M	-$25.35M	-$55.45M
YoY Change	-185.19%	-334.71%	79.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006CumulativeEffectPeriodOfAdoptionMember
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36257
	dei	Entity Registrant Name EntityRegistrantName	TRAVERE THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3611 Valley Centre Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	969-7879
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	TVTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63957899	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	179759000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165753000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	373414000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16689000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15914000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	7632000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	7313000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9283000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6718000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	586777000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	582827000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	116292000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10080000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11106000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21910000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23196000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	149920000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	148435000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10807000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11069000	usd
CY2022Q2	us-gaap	Assets Assets	779494000	usd
CY2021Q4	us-gaap	Assets Assets	776633000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11848000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15144000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	82694000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	75180000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12503000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16268000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	7300000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	7400000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4123000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3908000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6024000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6188000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	124492000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	124088000	usd
CY2022Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	374690000	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	226581000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16235000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	20379000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	68400000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	59700000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29359000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31497000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9605000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12276000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	622781000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	474521000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63838050	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63838050	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62491498	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62491498	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1036533000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1068634000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-878744000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-765966000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1082000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-562000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	156713000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	302112000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	779494000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	776633000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	54167000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	54617000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	102654000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	102024000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2051000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1651000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4189000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3296000	usd
CY2022Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	59681000	usd
CY2021Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	51807000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	99753000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	52979000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34965000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	99767000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71743000	usd
CY2022Q2	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	4907000	usd
CY2021Q2	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	1509000	usd
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	13987000	usd
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	10096000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	119618000	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	89932000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	234235000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	184888000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-65451000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-35315000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-131581000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-82864000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	782000	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	988000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1060000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1397000	usd
CY2022Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2972000	usd
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4852000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5487000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-10173000	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7578000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	662000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	216000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	688000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-877000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1528000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3648000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11317000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9653000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-66979000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38963000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142898000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92517000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	49000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	105000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	362000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-67032000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-39012000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-143003000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92879000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63638385	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63638385	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60571259	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60571259	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63387009	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63387009	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58431770	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58431770	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-67032000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-39012000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-143003000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92879000	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	1416000	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-227000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	1487000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	875000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-803000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-152000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2007000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-614000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66419000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39391000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-143523000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-92618000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-143003000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92879000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	20823000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	15204000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12694000	usd
	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	13987000	usd
	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	10096000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4247000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3602000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	766000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5522000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1741000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	962000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	132000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7578000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2368000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3226000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	777000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4056000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-17011000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2060000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	764000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2204000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1224000	usd
	tvtx	Change In Lease Assets And Liabilities Net ChangeInLeaseAssetsAndLiabilitiesNet	-492000	usd
	tvtx	Change In Lease Assets And Liabilities Net ChangeInLeaseAssetsAndLiabilitiesNet	5492000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2917000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-632000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	9070000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5700000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5313000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2127000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-453000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-92126000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19978000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	217325000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	242064000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	206529000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	406000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	148000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4598000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	16579000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8979000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5931000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-177513000	usd
	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1050000	usd
	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1050000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1271000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1399000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	316250000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9882000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	211324000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	947000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3074000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1529000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1275000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	114744000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	196056000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2681000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-49000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14006000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1484000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165753000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84772000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179759000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83288000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	208141000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	362689000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12352000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7288000	usd
CY2022Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	824000	usd
CY2021Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	319000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1815000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1496000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1416000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-227000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-803000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-152000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-98000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-67032000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-39012000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	156713000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	332303000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	302112000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	211213000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	20287000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14767000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	947000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	3074000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2065000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1710000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1487000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	875000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2007000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-614000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-143003000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92879000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	156713000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	332303000	usd
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics. </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ongoing novel coronavirus (COVID-19) pandemic has resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. While the impact of the COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the six months ended June 30, 2022, these governmental actions and similar actions that may be enacted in the future, and the widespread economic disruption arising from the pandemic, have the potential to materially impact our business and influence our business decisions. The extent and duration of the pandemic is unknown, and the future effects on our business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sparsentan is a novel investigational product candidate and has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerois (FSGS) and immunoglobulin A nephropathy (IgAN) in the U.S. and Europe. Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in rare kidney diseases.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pegtibatinase (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TVT-058) is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU). Pegtibatinase has been granted Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations by the FDA, as well as orphan drug designation in the United States and European Union. Pegtibatinase is currently being evaluated in the Phase 1/2 COMPOSE Study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. The Company</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> acquired pegtibatinase as part of the November 2020 acquisition of Orphan Technologies Limited.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chenodal (chenodeoxycholic acid or CDCA) is a naturally occurring bile acid that is approved for the treatment of people with radiolucent stones in the gallbladder. In January 2020, we randomized the first patients in our Phase 3 RESTORE Study to evaluate the effects of Chenodal in adult and pediatric patients with cerebrotendinous xanthomatosis (CTX), and the study enrollment remains open. The pivotal study is intended to support an NDA submission for marketing authorization of Chenodal for CTX in the United States. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are a participant in two Cooperative Research and Development Agreements ("CRADAs"), which form a multi-stakeholder approach to pool resources with leading experts, and incorporate the patient perspective early in the therapeutic identification and development process. We have partnered with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and leading patient advocacy organizations, CDG Care and Alagille Syndrome Alliance, aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome ("ALGS"), respectively. There are no treatment options currently approved for these diseases.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approved products:</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. </span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Cholbam</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Thiola</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Thiola EC</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</span></div>
CY2022Q2	tvtx	Number Of Phase3 Clinical Trials In Process NumberOfPhase3ClinicalTrialsInProcess	3	clinicaltrial
	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	The Company receives payments from its product sales based on terms that generally are within 30 days of delivery of product to the patient.
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	217300000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	206500000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	373414000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2022Q2	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	330856000	usd
CY2022Q2	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	0	usd
CY2022Q2	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	1835000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	329021000	usd
CY2022Q2	tvtx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	45032000	usd
CY2022Q2	tvtx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	0	usd
CY2022Q2	tvtx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	639000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	44393000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	375888000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2474000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	373414000	usd
CY2021Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	262345000	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	0	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	159000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	262186000	usd
CY2021Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	125254000	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	0	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	311000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	124943000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	387599000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	470000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	343766000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	2202000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	29648000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	272000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	373414000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	2474000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	380690000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	470000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	380690000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	470000	usd
CY2022Q2	tvtx	Debt Securities Available For Sale Unrealized Loss Position Amortized Cost DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost	375900000	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Position Amortized Cost DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost	381200000	usd
CY2019Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q2	tvtx	Lessee Operating Lease Aggregate Liability LesseeOperatingLeaseAggregateLiability	49500000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3019000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6200000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6386000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6578000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6775000	usd
CY2022Q2	tvtx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	11760000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	40718000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7236000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	33482000	usd
CY2022Q2	tvtx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	6067000	usd
CY2022Q2	tvtx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	5505000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21910000	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2500000	usd
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2400000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7600000	usd
	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	business
CY2022Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	179759000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	373414000	usd
CY2022Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	553173000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	75700000	usd
CY2022Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	75700000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	165753000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	552882000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	67100000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	67100000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	67100000	usd
	tvtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue	13987000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	2685000	usd
	tvtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Accrued FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsAccrued	2702000	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	75700000	usd
CY2022Q2	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	4900000	usd
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	14000000	usd
CY2021Q2	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	1500000	usd
	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	10100000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	149000000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	299345000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	283557000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	150361000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	136058000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	148984000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	147499000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	900000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	900000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7571000	usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6136000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14127000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12088000	usd
CY2022Q1	tvtx	Debt Instrument Repurchase Amount Including Accrued And Unpaid Interest DebtInstrumentRepurchaseAmountIncludingAccruedAndUnpaidInterest	213800000	usd
	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	3400000	usd
CY2022Q2	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	25763000	usd
CY2021Q4	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	26841000	usd
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	22871000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	25998000	usd
CY2022Q2	tvtx	Government Rebates Payable GovernmentRebatesPayable	14169000	usd
CY2021Q4	tvtx	Government Rebates Payable GovernmentRebatesPayable	7493000	usd
CY2022Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7501000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8402000	usd
CY2022Q2	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	6244000	usd
CY2021Q4	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3144000	usd
CY2022Q2	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	6146000	usd
CY2021Q4	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	3302000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	82694000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	75180000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63638385	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63638385	shares
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67032000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-67032000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60571259	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60571259	shares
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-39012000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-39012000	usd
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63387009	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63387009	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-143003000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-143003000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58431770	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58431770	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-92879000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-92879000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24171946	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18072393	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22147717	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18026005	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6800000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.87
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12637000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7510000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20823000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15204000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000	usd
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4673000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5205000	usd
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	653000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	255000	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2306000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	7313000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3900000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1853000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	7632000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4100000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16700000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15900000	usd
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares

Files In Submission

Name	View Source	Status
0001438533-22-000032-index-headers.html	Edgar Link	pending
0001438533-22-000032-index.html	Edgar Link	pending
0001438533-22-000032.txt	Edgar Link	pending
0001438533-22-000032-xbrl.zip	Edgar Link	pending
ex06302022311.htm	Edgar Link	pending
ex06302022312.htm	Edgar Link	pending
ex06302022321.htm	Edgar Link	pending
ex06302022322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tvtx-20220630.htm	Edgar Link	pending
tvtx-20220630.xsd	Edgar Link	pending
tvtx-20220630_cal.xml	Edgar Link	unprocessable
tvtx-20220630_def.xml	Edgar Link	unprocessable
tvtx-20220630_g1.gif	Edgar Link	pending
tvtx-20220630_htm.xml	Edgar Link	completed
tvtx-20220630_lab.xml	Edgar Link	unprocessable
tvtx-20220630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2022 Q3 Form 10-Q Financial Statement

#000143853322000032 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2022 Q3 Form 10-Q Financial Statement

#000143853322000032 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx